October 14, 2025 · The Frozen Lotus Temple, Mount Song, Henan Province, China · 08:00 CST
The table in the main briefing room had four cups of coffee and a map of Ireland on it. The map was not decorative.
Alen had been in the room since six-thirty. The wall display was running — two windows, one showing the Teach Mharcus facility layout with the medical wing highlighted in amber, one showing a biological timeline that Rebecca had built over the previous two days and that ran from October 14, 2025 to March 28, 2026 in five colour-coded phases. The coffee had been made by someone else. He had drunk one cup and not noticed the second going cold.
Rebecca came in at seven forty-five and added three pages of handwritten synthesis notes to the stack on the table without comment. She had been in the laboratory since five.
Jake arrived at eight exactly, read the room in two seconds, and sat down in the chair furthest from the wall display with the specific posture of a man who understood that this was serious and had decided his job was to listen carefully and not break anything.
Yoko came in last, carrying her own coffee, and sat beside Jake with the focused, composed quality she had been carrying since the Black Forest — the specific, compressed quality of someone who had survived something serious and had converted the adrenaline of it into a permanent state of readiness. Three days of sleep and regular meals had not quite smoothed the edges. They might not for a while.
Alen looked at the four of them. He stood.
"Five months," he said. "That is what the synthesis and the full treatment protocol require. I need to explain why that is the number before we discuss the operational structure."
∗ ∗ ∗
He turned to the display. The biological timeline expanded to fill the wall.
"Manuela Hidalgo has been carrying T-Veronica since 2001," he said. "Twenty-four years of active infection, managed through continuous organ transplants. The transplant protocol works by denying the virus the time it needs to complete its integration cycle — every six to eight weeks a new organ is introduced, the viral clock resets, and the mutation cascade never advances. It is not a treatment. It is a permanent holding pattern."
Yoko said, "I know. Three weeks of it at the Black Forest facility."
"Then you know what the holding pattern costs," Alen said. He looked at her steadily. "The transplant protocol requires a continuous supply of compatible biological material. The Connections were sourcing that material through channels I will not describe in detail because the description serves no useful purpose here. What I will say is that the protocol ends with the treatment. Not because we are removing the virus — because we are making the virus static."
Yoko was quiet.
"The T-Veronica advancement architecture," he continued, "is a specific component of the viral structure — the element derived from the queen ant retroviral genome that drives the virus toward continuous spread and progressive mutation. That is the target. Not the Progenitor root, not the integration itself. Just the advancement mechanism. We sever it. The virus stops moving. The organ dependency ends. Manuela stabilises at her current integration level permanently."
"The fire," Yoko said. "Her blood."
"The combustible blood property was produced during the partial integration that the transplant protocol could not prevent," Rebecca said. "It is part of her biology now. It stays. What does not stay is the threat of full mutation."
Yoko absorbed this. "You are not curing her."
"We are freeing her," Alen said. The distinction he meant was precise and he was making it deliberately. "A cure implies restoring a prior state. There is no prior state to restore — she has been carrying this virus since she was fifteen years old. Her biology has adapted around it. The goal is not to return her to the person she was before 2001. The goal is to remove the danger, remove the dependency, and give her the choice about what comes next. If she wants full viral dissolution through the completed Elpis compound, that becomes available to her after the five months. That is her decision, made freely, with full information. Not ours."
Yoko was quiet for a long moment. Then she nodded. "Yes," she said. "I understand the difference."
∗ ∗ ∗
"You treated something similar before," Yoko said. "You said the Romania operation established the conceptual approach."
"The principle is the same," Alen said. "Different biology, different mechanism, same core decision: do not erase, sever. In Romania the target was the synaptic bridge between a Cadou parasite and the Megamycete's consciousness network. The Cadou integration in the subject was decades old and deeply structural. Destroying the Cadou outright would have caused fatal feedback through the bio-signal connection. The correct tool was a selective severance compound that targeted only the specific bridge point without disturbing the integration architecture around it." He paused. "In Manuela's case the target is the viral advancement mechanism — the queen ant retroviral component driving the mutation progression. The Progenitor root architecture, the partial integration, the functional biological properties — all of that we leave intact."
"The woman you treated in Romania," Yoko said carefully. "How old was the integration?"
"Years," Alen said.
"Not decades. Not twenty-four years."
"No. Manuela's case is more complex. That is part of why the timeline is five months rather than shorter."
Yoko looked across the table at Rebecca. "Is it possible? Not probable. Possible."
"It is more than possible," Rebecca said. "The complexity is what makes it manageable, not what makes it dangerous. Manuela's T-Veronica has been permanently reset for twenty-four years — it has never completed its integration, which means it has never stabilised into a fixed biological architecture the way Alexia Ashford's did. It is still in an active-instability state. That instability is what we are working with rather than against. We can influence it in ways we could not influence a fully-completed integration."
She was explaining it the way she explained things when she wanted someone to understand rather than simply accept. Yoko's background was enough to follow it.
"The Alexia model," Yoko said. "Fifteen years in cryo. Full integration."
"Complete symbiosis," Rebecca confirmed. "T-Veronica became T-Alexia — a personalised strain, specific to her cellular architecture, finished and stable. If we were dealing with that model in Manuela, the approach would be completely different." She paused. "We are not. Manuela's virus has been denied its completion for twenty-four years. In that specific biological state, the advancement mechanism is the one vulnerable target. We find it, we sever it, and the rest of the structure loses the engine that was driving it toward crisis."
Yoko said, "And the organ transplants?"
"Month one of the protocol," Alen said. "The Anchor compound halts viral advancement within seventy-two hours of the first administration if the synthesis is correct. The transplant dependency begins winding down from that point. By week four we should have confirmed zero advancement across all monitored viral markers. After that the transplants are no longer medically necessary." He paused. "You will need to be present through the month-one monitoring phase. You have three weeks of direct observation of her biology at the Black Forest facility. Your knowledge of her current baseline is something no standardised clinical assessment can replace this quickly."
Yoko straightened slightly. It was the specific posture of someone who had been handed a genuine responsibility rather than a courtesy role and who understood the difference. "Yes," she said. "I will be there."
Yoko paused again, then looked at Rebecca with a slightly different expression. "You said her mutation was mycology-based. The woman from Romania. The doll maker." A beat. "Why does she look young if the integration was years old?"
Rebecca laughed — soft, genuine. "You really have not been briefed on our small family, have you." She glanced at Alen. "I will explain Donna separately. The short answer is that the Cadou's effect on its host biology is not limited to the neural architecture. There are secondary biological consequences that affect cellular aging in ways we are still documenting." She picked up her cup. "She is fine, by the way. She is upstairs making dolls with Ruby."
Yoko blinked. Then, after a moment: "I will wait for the full explanation."
∗ ∗ ∗
Alen turned back to the wall display. The facility map of Teach Mharcus came back up — the stone building in County Donegal, the restored Victorian structure embedded in the hillside, the medical wing in amber.
"The operational structure for the five months," he said. "Rebecca and I will be at Teach Mharcus. The synthesis requires the Marcus Bio-Core, the White Queen Archive once she is restored, and the 1991 Elpis prototype as the foundational compound. All of that is in Ireland. That is where the work happens."
"Manuela's treatment begins at Teach Mharcus," Rebecca said. "Not in China. The facility has a fully equipped medical wing — I designed the configuration after February 2021. The level of biological monitoring we need for the five-phase protocol is not something I can run remotely."
Yoko said, "I am coming to Ireland."
"Yes," Alen said. "You are Manuela's caretaker. The specialist team Rebecca has assembled will be there — three virologists from her inner circle, two surgeons, a dedicated pharmacological technician. They are cleared to the level this work requires. They do not know the full synthesis programme; they know the treatment protocol for the patient in their care. Those are separate compartments."
"For security," Alen continued, turning to Jake, "you are in charge of the facility ground. Not the medical wing — that is Rebecca's operational space and you are not in it unless she calls you in. But the perimeter, the approaches, the access protocols. Ingrid Hunnigan has a DSO team standing by — appointed quietly, no formal documentation trail. Six people who understand that their job is to make sure nothing reaches the building rather than to respond after it has."
Jake said, "I can work with that. What is the threat picture?"
"The Connections know Manuela was extracted from the Black Forest facility. They know the facility was destroyed. They do not know where she is." Alen said it with the flat certainty of someone who has already run the intelligence picture three times. "The location of Teach Mharcus does not appear in any Umbrella corporate archive, any BSAA intelligence database, or any Connections operational file. As far as the world's collective institutional knowledge is concerned, it does not exist."
"How confident are you in that?"
"Ortega's team spent ten months building it in complete operational silence. The power architecture is off every satellite grid. The geothermal tap is documented as a heritage agricultural system for the landholding." A pause. "I am confident."
Jake absorbed this with the focused, practical quality he brought to operational briefs. "Ingrid's team, six people, perimeter and approach coverage. I run the ground. Medical wing is Rebecca's. Nobody gets through without going through me first."
"Yes," Alen said.
"Good. I can do that."
"I know you can," Alen said. It was simply stated. Jake heard it and said nothing.
∗ ∗ ∗
Rebecca stood and walked to the display, pulling up the phase timeline.
"Five phases," she said. "Month one: Anchor synthesis and first administration. Viral advancement halted, transplant dependency wind-down begins, Manuela's biological baseline established under stable conditions. Month two: Foundation — hereditary disease remediation. The condition that was killing her before T-Veronica entered her body in 2001 gets addressed permanently so that when the viral architecture eventually changes, she does not step out of one danger and into the one she came from. Months three and four: Elpis final synthesis. The completed antiviral compound, built from Spencer's 1991 prototype using the White Queen Archive data to close the thirty-year sequencing gap. Month five: Administration and the question of what Manuela chooses."
"The question of what she chooses," Yoko said.
"Whether she wants full viral dissolution when the Elpis compound is complete," Rebecca said. "That decision belongs to her and no one else. Our job for the first four months is to make sure she is healthy enough and informed enough to make it freely. Our job in month five is to follow her decision."
Yoko looked at the timeline for a long moment. Then she said, quietly: "She is thirty-nine years old. She has been living in a holding pattern for twenty-four of those years. She has never been in a position to make a free decision about her own body."
"No," Rebecca said. "She has not."
"Then month five," Yoko said, "is the most important month."
"Yes," Rebecca said. "It is."
Alen looked at Yoko across the table. She had three weeks of direct knowledge of the woman in the medical bay above them. She had managed Manuela's transplant protocol, monitored her vitals, spent three weeks in a Connections black-site keeping a thirty-nine-year-old T-Veronica carrier alive through another round of organ replacement, all while simultaneously mapping guard rotations and smuggling an encrypted signal through a confiscated phone at exactly the right moment. He was not going to say any of that out loud because Yoko would not receive it well and because the table did not require it. He said:
"You are not a caretaker in the passive sense. You are part of the team."
Yoko looked at him steadily. "Understood, Mr. Richard."
∗ ∗ ∗
Rebecca began collecting her synthesis notes from the table. The map of Ireland stayed. The timeline stayed on the wall.
"We leave tomorrow morning," Alen said. "The Night-Wing is configured for the full cargo load — the Elpis case, the file archive, the White Queen disk. The medical team is already in transit to Donegal. The facility is ready."
"What about the others?" Jake said. "Zoe. Cindy. Donna. Ruby."
"They stay here for the duration. The temple is their home and it is secure. Ivan's patrol protocols run continuously. Linda and her family are not going anywhere. If there is a situation that requires the full group, Trinity flags me and we assess." He looked at Jake. "You will be in Ireland. That is where the work is."
Jake nodded. He was quiet for a moment. Then: "She is going to be all right? Manuela."
The question was not operational. Alen heard it for what it was.
"The protocol is sound," he said. "The synthesis is achievable. The timeline is realistic." He paused. "And she survived twenty-four years of something that should have killed her in the first month. She is not a fragile subject."
Jake made a sound. Not quite a laugh. Something that acknowledged the truth in it.
Yoko stood. She straightened the pages of notes in front of her — a reflex, the specific organisational habit of someone for whom tidying a small thing was a way of steadying after a large one. "I will go and sit with her," she said. "She may be waking from the cryo recovery."
"She may," Rebecca said. "Tell me if her vitals shift."
"I will."
Yoko left. Jake picked up his coffee, found it cold, drank it anyway, and followed her out.
The room was down to two.
Rebecca looked at the timeline on the wall. Five colour-coded phases, each one representing a month of work they had been building toward for years from different directions. The amber of the medical wing at Teach Mharcus. The March endpoint in white.
"She asked the right question," she said. "Yoko. Month five."
"Yes," Alen said.
"Whatever Manuela decides in month five — either answer is the correct one."
"Yes."
Rebecca turned off the display. The room went back to ordinary morning light. She picked up her synthesis notes, tucked them under her arm, and looked at him with the specific quality she had when she had already decided to say something and was choosing the moment for it.
"Project HOPE," she said. "The name she gave the sample in Chicago. 2017."
He looked at her.
"I labelled it before I knew whose blood it was," she said. "Before I knew any of it. I just looked at what was in the sample and I called it that because it was the word the biology produced." She paused. "I think I knew, even then, that it was going somewhere worth going."
He picked up his own cold coffee. He was quiet for a moment.
"The mission begins tomorrow," he said.
"Yes," she said.
She walked out. He turned back to the window — the morning light on the mountain, the specific, clean quality of October at altitude, the world outside the glass going about its work entirely unaware of what was going to happen in a stone building in Donegal across the next five months.
He stood there for a while. Then he went to pack.
∗ ∗ ∗
— END OF CHAPTER SIXTY-FOUR —